. Author manuscript; available in PMC: 2023 Jun 1.

Published in final edited form as: J Allergy Clin Immunol. 2021 Dec 30;149(6):1992–1997.e12. doi: 10.1016/j.jaci.2021.11.027

Table III.

Mendelian randomization results using inverse variance weighted method for 3 sRAGE variants in relation to UK Biobank asthma GWAS

Exposure	Outcome	# of SNPs	Beta	SE	OR (95% CI)	p
sRAGE	Self-reported asthma	3	−0.027	0.009	0.973 (0.955, 0.992)	0.005
sRAGE	Doctor-diagnosed asthma	3	−0.029	0.011	0.972 (0.950, 0.993)	0.011

Instrumental variables used in Mendelian randomization analysis were three cis-pQTLs derived from 6,861 Framingham Heart Study participants: rs2070600, rs6923504, rs9266529. Two GWAS of asthma were used in two-sample MR analyses: one for self-reported asthma and one for doctor-diagnosed asthma (see Methods for details).

Mendelian randomization results revealed sRAGE to be putatively causally implicated with a slight protective effect in both self-reported and doctor-diagnosed asthma; results are reported in odds ratios (OR) per 1 standard error (SE) increment in inverse rank-normalized sRAGE levels.

Abbreviations: OR = Odds Ratio; SE = Standard Error; SNP = Single Nucleotide Polymorphism; sRAGE = Soluble Receptor for Advanced Glycation End-Products; 95% CI = 95% Confidence Interval